[ET Net News Agency, 4 August 2021] Akeso, Inc. (09926) said the company has received
the approval from the National Medical Products Administration of the People's Republic of
China to initiate an open-label, multicentre phase Ib/II clinical trial for the global
first-in-class novel drug Cadonilimab (PD-1/CTLA-4 bi-specific antibody, research and
development code: AK104), an immuno-oncology therapy independently developed by the
company, in combination with VEGFR-2 monoclonal antibody (research and development code:
AK109) for treatment of advanced solid tumours.
The company has previously initiated a phase I clinical trial of AK109 for treatment of
advanced solid tumours and phase Ib/II clinical trial of AK109 in combination with
Cadonilimab for treatment of gastric cancer in China. (RC)